Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for autoimmune and rare diseases. Headquartered in Waltham, Massachusetts, the company's lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to inhibit B-cell activity by targeting CD19 and FcγRIIb. Obexelimab is being evaluated for the treatment of conditions such as Immunoglobulin G4-Related Disease (IgG4-RD), multiple sclerosis, and systemic lupus erythematosus. In addition to obexelimab, Zenas is advancing orelabrutinib, a selective oral small molecule BTK inhibitor targeting progressive multiple sclerosis. The company operates globally, leveraging strategic partnerships to expand its clinical development and prepare for potential commercialization in the United States and Europe.
